Compare iShares MSCI Indonesia ETF (EIDO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Novartis AG — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 656.3× iShares MSCI Indonesia ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Novartis AG for 82 Days on average.
| EIDO | NVS | |
|---|---|---|
Market Cap | $409.22M | $268.57B |
Volume | 879,527 | 1,532,573 |
52-Week High | $19.22 | $168.62 |
52-Week Low | $10.80 | $121.80 |
Typical Hold Time | 76 Days | 82 Days |
Sector | — | Health |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.89, up 0.25% with bearish technical signals from moving averages. The ETF faces headwinds from foreign capital outflows in Asian equities and limited upside from its heavy financials weighting. Recent news highlights Indonesia's underperformance despite commodity gains, with trading volume declining 21% below average.
Outlook remains cautious given technical downtrend and sector concentration risks. The ETF's bargain 8.7x P/E offers value but weak price action and low EPS growth constrain momentum. Key risks include regional capital rotation and dependence on financial sector performance.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
